Medication remains a cornerstone of treatment for most mental illnesses. For this reason, MAPrc is committed to investigating new and improved medications for serious mental illnesses such as schizophrenia, bipolar affective disorder, major depression, anxiety and other disorders.

In keeping with our research philosophy of equality, respect and understanding, the clinical trials that we undertake are limited in number and aim to provide better symptom resolution. We do not undertake studies that contain placebo-only groups and we require that the active medications being trialled are ones that have been shown in preliminary trials to be superior to currently available medications. During trials, we take care to monitor the participants’ subjective assessments of their experience, the effects of the trial medications and other general responses. We also invite carers to give their views and opinions about the treatments being studied.

In recent years, a number of new and improved treatments have become available, and advances in biotechnology are paving the way for new techniques for drug discovery. We believe that the future holds substantial hope for new and better treatment options for people living with devastating mental illnesses.


Psychopharmacology Research Team


Principal Investigator
Prof. Jayashri Kulkarni

Research Manager
Mr Anthony de Castella



 MAPrc Monash Alfred Psychiatry Research Centre, Level 4, 607 St Kilda Road, Melbourne 3004

 © MAPrc 2013. Designed and hosted by Infoxchange Australia